ttx-030
mAbexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 10, 2019 (NCT03884556)
Timeline
Indications
Mechanism of action
- Ectonucleoside triphosphate diphosphohydrolase 1Supplementation
ENTPD1 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06119217 | Phase 2 | Dec 31, 2023 | AbbVie, Trishula Therapeutics |
| NCT04306900 | Phase 1 | Mar 31, 2020 | AbbVie, Tizona Therapeutics, Inc |
| NCT03884556 | Phase 1 | Apr 10, 2019 | NEXT Oncology, SCRI Development Innovations, Sylvester Comprehensive Cancer Center, Tizona Therapeutics, Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 2 | 0 | 2 | 2020 |
| Tizona Therapeutics, Inc | For profit | 2 | 2 | 1 | 2019 |
| NEXT Oncology | For profit | 1 | 0 | 1 | 2019 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2019 |
| Sylvester Comprehensive Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Trishula Therapeutics | For profit | 1 | 1 | 1 | 2023 |
6 organizations
Page 1 / 1